KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Common Equity (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Common Equity for 17 consecutive years, with $7.5 billion as the latest value for Q4 2025.

  • Quarterly Common Equity rose 13.46% to $7.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.5 billion through Dec 2025, up 13.46% year-over-year, with the annual reading at $7.5 billion for FY2025, 13.46% up from the prior year.
  • Common Equity for Q4 2025 was $7.5 billion at Bio-Rad Laboratories, up from $6.7 billion in the prior quarter.
  • The five-year high for Common Equity was $15.3 billion in Q3 2021, with the low at $6.6 billion in Q4 2024.
  • Average Common Equity over 5 years is $9.1 billion, with a median of $8.6 billion recorded in 2022.
  • The sharpest move saw Common Equity skyrocketed 73.74% in 2021, then plummeted 44.71% in 2022.
  • Over 5 years, Common Equity stood at $13.7 billion in 2021, then dropped by 29.74% to $9.6 billion in 2022, then dropped by 9.09% to $8.7 billion in 2023, then fell by 24.85% to $6.6 billion in 2024, then grew by 13.46% to $7.5 billion in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $7.5 billion, $6.7 billion, and $7.1 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.